T cells gain superior memory through new reprogramming method, boosting cancer-fighting abilities

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
The Pharma Letter

AbbVie punts up to ~$5 billion on RemeGen bispecific antibody

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...

Body Resurrects Cells Marked For Death, Solving a 50-Year Mystery

When tissue is severely damaged, surviving cells can respond in a concentrated burst of biological repair known as ...
TMCnet

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...

HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...